December 2025: Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial

Dr. Suresh Durgam (Intra-Cellular Therapies, a Johnson & Johnson Company, Bedminster, NJ) joins AJP Audio to discuss a phase 3 randomized controlled trial looking at the use of the antipsychotic medication lumateperone as adjunctive to antidepressant therapy in the treatment of patients with major depressive disorder. Afterwards, AJP Editor-in-Chief Dr. Ned Kalin discusses the rest of the December issue of the Journal. 00:48 Durgam interview 03:09 Mechanism of action 04:44 Patient-reported outcomes 06:31 Immediate clinical implications 07:32 Limitations 08:08 Further research 09:25 Kalin interview 09:38 Durgam et al. 13:09 Lin et al. 17:22 Brodsky et al. Transcript Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it.

You can listen to December 2025: Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial online on Radio and Podcast. Open the player on this page to stream the available audio.

December 2025: Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial is an episode from American Journal of Psychiatry Audio by American Psychiatric Association Publishing.

This episode is 22:12 long.

This episode was published on Dec 1, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from American Journal of Psychiatry Audio when more episodes are available from the podcast feed.